Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
81 hedge funds and large institutions have $334M invested in Bellicum Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 41 increasing their positions, 16 reducing their positions, and 9 closing their positions.
156% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 16
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
14% more funds holding
Funds holding: 71 → 81 (+10)
2% less capital invested
Capital invested by funds: $340M → $334M (-$5.53M)
65% less call options, than puts
Call options by funds: $983K | Put options by funds: $2.8M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.5M |
| 2 |
Millennium Management
New York
|
+$6.54M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$5.64M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.25M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$12.1M |
| 2 |
Jennison Associates
New York
|
-$9.33M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$5.21M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$5.08M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$2.08M |
BLCM Hedge Fund Activity: Q2 2015 in Review
81 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2015, worth a combined $334M — down 1.6% from $340M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BLCM positions and 9 closed out — a net gain of 10 holders — while 41 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $24.5M. The largest seller was Perceptive Advisors, cutting an estimated $12.1M.
- 81 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2015, up from 71 in Q1 2015.
- Funds reported $334M of Bellicum Pharmaceuticals, Inc. stock for Q2 2015, down 1.6% quarter-over-quarter.
- 19 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2015 and 9 closed out, a net change of +10 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2015 was Fidelity Investments, an estimated $24.5M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2015 was Perceptive Advisors, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2015.